- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04339270
만성 기도 질환, 점액 유변학 및 악화 (COPD-CARhE)
만성 기도 질환, 점액 유변학 및 악화: COPD 환자의 무작위 대조 시험
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.
연구 개요
상태
정황
상세 설명
The secondary objectives are to compare between the 2 arms:
- exacerbation number according to their severity (observed throughout the duration of the study);
- the evolution of the symptoms, the rheology of the sputum, and the pulmonary function (measurements repeated every three months);
- medication consumption and adverse events (monitored throughout the duration of the study);
- patient trajectories during follow-up;
- the overall clinical improvement at the end of the study and the evolution of the quality of life (measurements repeated every 3 months);
- the change in biomarkers of interest (baseline versus end of study).
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Jérémy Charriot, MD
- 전화번호: 04 67 33 67 33
- 이메일: j-charriot@chu-montpellier.fr
연구 연락처 백업
- 이름: Arnaud BOURDIN, MD
- 전화번호: 04 67 33 67 33
- 이메일: a-bourdin@chu-montpellier.fr
연구 장소
-
-
-
Bordeaux, 프랑스
- 모병
- University Hospitals of Bordeaux
-
수석 연구원:
- Maéva Zysman, MD, PhD
-
Montpellier, 프랑스, 34925
- 모병
- University Hospitals of Montpellier
-
수석 연구원:
- Jérémy Charriot, MD
-
부수사관:
- Arnaud Bourdin, MD, PhD
-
부수사관:
- Anne-Sophie Gamez, MD
-
부수사관:
- Jean Romain, MD
-
Toulouse, 프랑스
- 모병
- University Hospitals of Toulouse
-
수석 연구원:
- Laurent Guilleminault, MD
-
부수사관:
- Alain Didier, MD, PhD
-
부수사관:
- Danielle Brouquieres, MD
-
부수사관:
- Nicolas Guibert, MD
-
부수사관:
- Sandrine Pontier Marchandise, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subjets between 40 - 85 years (included)
- Written and signed informed consent form
- Subjects must be able to attend all planned visits and comply with all test procedures
- Beneficiary of or affiliated with the French social security system
- Man or woman with chronic obstructive pulmonary disease for at least 1 year defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and validated by the clinical investigator
- Optimal treatment according to GOLD class severity C or D recommendations
- >=3 exacerbation (regardless of severity: mild-moderate-severe) or ≥ 1 severe exacerbations (requiring hospitalization) in the past 12 months
- Spontaneous or induced sputum production
- Electrocardiogram: corrected distance between Q and T waves (QTC) <450 ms in men, QTC <470 ms in women
- Normal audiogram for age or absence of contraindication to azithromycin for long course according to Oto-Rhino-Laryngological specialist opinion
Exclusion Criteria:
- Pregnancy or breastfeeding
- Patients who are prisoners or under other forms of judicial protection
- Patients under any form of guardianship
- Participation in another interventional protocol, (current or during the month preceding inclusion)
- Received azithromycin in the past 3 months
- Patient whose primary diagnosis is bronchial dilation based on CT scan documentation
- Known hypersensitivity to azithromycin, erythromycin, any other macrolide, ketolide or any of the excipients of the azithromycin-based specialty used
- Concomitant use of medication contraindicated with azithromycin (dihydroergotamine, ergotamine, cisapride, colchicine)
- Other respiratory diseases or associated lung infections
- Severe hepatic insufficiency and severe cholestasis (a liver biological test will be carried out if clinical suspicion)
- Renal impairment with creatinine clearance < 40 mL/min
- Patients with hematological malignancies who have undergone allogeneic hematopoietic stem cell transplantation
- Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary disease) due to the presence of lactose in the specialty Zithromax.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Azithromycin according to symptoms
Patients randomized to this arm will be prescribed azithromycin in function of their symptoms. |
Patients randomized to the "standardized comparator arm" will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score <70 to homogenize practices between centers). CASA-Q will be evaluated every 3 months.
|
|
실험적: Azithromycin according to rheology
Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology. |
Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score <70). The rheology of mucus will be quantified every 3 months.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The main outcome measure is the number of exacerbations over the 12 months of follow-up.
기간: 12 months
|
An exacerbation is defined according to French recommendations as an "acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond [normal] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and / or oral corticosteroid therapy)." |
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
유변학: 점액의 탄성 계수(G')
기간: 기준선(0일차)
|
기준선(0일차)
|
|
|
유변학: 점액의 탄성 계수(G')
기간: 3 개월
|
3 개월
|
|
|
유변학: 점액의 탄성 계수(G')
기간: 6 개월
|
6 개월
|
|
|
유변학: 점액의 탄성 계수(G')
기간: 9개월
|
9개월
|
|
|
유변학: 점액의 탄성 계수(G')
기간: 12 개월
|
12 개월
|
|
|
유변학: 점성 모듈(G'')
기간: 기준선(0일차)
|
기준선(0일차)
|
|
|
유변학: 점성 모듈(G'')
기간: 3 개월
|
3 개월
|
|
|
유변학: 점성 모듈(G'')
기간: 6 개월
|
6 개월
|
|
|
유변학: 점성 모듈(G'')
기간: 9개월
|
9개월
|
|
|
유변학: 점성 모듈(G'')
기간: 12 개월
|
12 개월
|
|
|
유변학: 비율 G'' / G'
기간: 기준선(0일차)
|
기준선(0일차)
|
|
|
유변학: 비율 G'' / G'
기간: 3 개월
|
3 개월
|
|
|
유변학: 비율 G'' / G'
기간: 6 개월
|
6 개월
|
|
|
유변학: 비율 G'' / G'
기간: 9개월
|
9개월
|
|
|
유변학: 비율 G'' / G'
기간: 12 개월
|
12 개월
|
|
|
유변학: 임계 제약 조건(tau-C).
기간: 기준선(0일차)
|
기준선(0일차)
|
|
|
유변학: 임계 제약 조건(tau-C).
기간: 3 개월
|
3 개월
|
|
|
유변학: 임계 제약 조건(tau-C).
기간: 6 개월
|
6 개월
|
|
|
유변학: 임계 제약 조건(tau-C).
기간: 9개월
|
9개월
|
|
|
유변학: 임계 제약 조건(tau-C).
기간: 12 개월
|
12 개월
|
|
|
폐활량계: 1분 내 강제 호기량(FEV1)
기간: 기준선(0일)
|
기준선(0일)
|
|
|
폐활량계: 1분 내 강제 호기량(FEV1)
기간: 3 개월
|
3 개월
|
|
|
폐활량계: 1분 내 강제 호기량(FEV1)
기간: 6 개월
|
6 개월
|
|
|
폐활량계: 1분 내 강제 호기량(FEV1)
기간: 9개월
|
9개월
|
|
|
폐활량계: 1분 내 강제 호기량(FEV1)
기간: 12 개월
|
12 개월
|
|
|
폐활량계: 강제 폐활량(FVC)
기간: 기준선(0일)
|
기준선(0일)
|
|
|
폐활량계: 강제 폐활량(FVC)
기간: 3 개월
|
3 개월
|
|
|
폐활량계: 강제 폐활량(FVC)
기간: 6 개월
|
6 개월
|
|
|
폐활량계: 강제 폐활량(FVC)
기간: 9개월
|
9개월
|
|
|
폐활량계: 강제 폐활량(FVC)
기간: 12 개월
|
12 개월
|
|
|
폐활량계: FEV1/FVC
기간: 기준선(0일)
|
기준선(0일)
|
|
|
폐활량계: FEV1/FVC
기간: 3 개월
|
3 개월
|
|
|
폐활량계: FEV1/FVC
기간: 6 개월
|
6 개월
|
|
|
폐활량계: FEV1/FVC
기간: 9개월
|
9개월
|
|
|
폐활량계: FEV1/FVC
기간: 12 개월
|
12 개월
|
|
|
폐 용적에 대한 혈량 측정법: 잔여 용적(RV)
기간: 기준선(0일)
|
기준선(0일)
|
|
|
폐 용적에 대한 혈량 측정법: 잔여 용적(RV)
기간: 3 개월
|
3 개월
|
|
|
폐 용적에 대한 혈량 측정법: 잔여 용적(RV)
기간: 6 개월
|
6 개월
|
|
|
폐 용적에 대한 혈량 측정법: 잔여 용적(RV)
기간: 9개월
|
9개월
|
|
|
폐 용적에 대한 혈량 측정법: 잔여 용적(RV)
기간: 12 개월
|
12 개월
|
|
|
폐 용적에 대한 혈량측정법: 기능적 잔기 용량(FRC)
기간: 기준선(0일)
|
기준선(0일)
|
|
|
폐 용적에 대한 혈량측정법: 기능적 잔기 용량(FRC)
기간: 3 개월
|
3 개월
|
|
|
폐 용적에 대한 혈량측정법: 기능적 잔기 용량(FRC)
기간: 6 개월
|
6 개월
|
|
|
폐 용적에 대한 혈량측정법: 기능적 잔기 용량(FRC)
기간: 9개월
|
9개월
|
|
|
폐 용적에 대한 혈량측정법: 기능적 잔기 용량(FRC)
기간: 12 개월
|
12 개월
|
|
|
폐 용적에 대한 혈량 측정법: 총 폐활량(TLC)
기간: 기준선(0일)
|
기준선(0일)
|
|
|
폐 용적에 대한 혈량 측정법: 총 폐활량(TLC)
기간: 3 개월
|
3 개월
|
|
|
폐 용적에 대한 혈량 측정법: 총 폐활량(TLC)
기간: 6 개월
|
6 개월
|
|
|
폐 용적에 대한 혈량 측정법: 총 폐활량(TLC)
기간: 9개월
|
9개월
|
|
|
폐 용적에 대한 혈량 측정법: 총 폐활량(TLC)
기간: 12 개월
|
12 개월
|
|
|
폐용적에 대한 혈량측정법: RV/TLC
기간: 기준선(0일)
|
기준선(0일)
|
|
|
폐용적에 대한 혈량측정법: RV/TLC
기간: 3 개월
|
3 개월
|
|
|
폐용적에 대한 혈량측정법: RV/TLC
기간: 6 개월
|
6 개월
|
|
|
폐용적에 대한 혈량측정법: RV/TLC
기간: 9개월
|
9개월
|
|
|
폐용적에 대한 혈량측정법: RV/TLC
기간: 12 개월
|
12 개월
|
|
|
연구 내내 약물 소비.
기간: 12 개월
|
12 개월
|
|
|
부작용의 수는 연구 전반에 걸쳐 기록될 것입니다.
기간: 12 개월
|
12 개월
|
|
|
혈청 클럽 세포 분비 단백질
기간: 기준선(0일)
|
기준선(0일)
|
|
|
혈청 클럽 세포 분비 단백질
기간: 12 개월
|
12 개월
|
|
|
객담 세균학
기간: 기준선(0일)
|
기준선(0일)
|
|
|
객담 세균학
기간: 12 개월
|
12 개월
|
|
|
The number of mild exacerbations throughout follow-up
기간: 12 months
|
A mild exacerbation does not require new additional medicine. |
12 months
|
|
The number of moderate exacerbations throughout follow-up
기간: 12 months
|
Moderate exacerbations require antibiotics or oral corticosteroids (but not hospitalization). |
12 months
|
|
The number of severe exacerbations throughout follow-up
기간: 12 months
|
Severe exacerbations require hospitalization. |
12 months
|
|
COPD Assessment Test (CAT)
기간: Baseline (Day 0)
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
Baseline (Day 0)
|
|
COPD Assessment Test (CAT)
기간: 3 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
3 months
|
|
COPD Assessment Test (CAT)
기간: 6 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
6 months
|
|
COPD Assessment Test (CAT)
기간: 9 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
9 months
|
|
COPD Assessment Test (CAT)
기간: 12 months
|
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status. |
12 months
|
|
Sino Nasal Outcome Test 22
기간: Baseline (Day 0)
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
Baseline (Day 0)
|
|
Sino Nasal Outcome Test 22
기간: 3 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
3 months
|
|
Sino Nasal Outcome Test 22
기간: 6 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
6 months
|
|
Sino Nasal Outcome Test 22
기간: 9 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
9 months
|
|
Sino Nasal Outcome Test 22
기간: 12 months
|
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes). |
12 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
기간: Baseline (Day 0)
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
Baseline (Day 0)
|
|
Cough and sputum assessment questionnaire (CASA-Q)
기간: 3 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
3 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
기간: 6 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
6 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
기간: 9 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
9 months
|
|
Cough and sputum assessment questionnaire (CASA-Q)
기간: 12 months
|
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings. |
12 months
|
|
Visual analogue scale for dyspnea
기간: Baseline (Day 0)
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
Baseline (Day 0)
|
|
Visual analogue scale for dyspnea
기간: 3 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
3 months
|
|
Visual analogue scale for dyspnea
기간: 6 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
6 months
|
|
Visual analogue scale for dyspnea
기간: 9 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
9 months
|
|
Visual analogue scale for dyspnea
기간: 12 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible). |
12 months
|
|
Visual analogue scale for coughing
기간: Baseline (Day 0)
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
Baseline (Day 0)
|
|
Visual analogue scale for coughing
기간: 3 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
3 months
|
|
Visual analogue scale for coughing
기간: 6 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
6 months
|
|
Visual analogue scale for coughing
기간: 9 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
9 months
|
|
Visual analogue scale for coughing
기간: 12 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible). |
12 months
|
|
Visual analogue scale for sputum production
기간: Baseline (Day 0)
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
Baseline (Day 0)
|
|
Visual analogue scale for sputum production
기간: 3 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
3 months
|
|
Visual analogue scale for sputum production
기간: 6 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
6 months
|
|
Visual analogue scale for sputum production
기간: 9 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
9 months
|
|
Visual analogue scale for sputum production
기간: 12 months
|
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible). |
12 months
|
|
Episodes of exacerbation throughout the study
기간: 12 months
|
For each exacerbation, the beginning and end dates will be recorded. |
12 months
|
|
Episodes of hospitalization throughout the study
기간: 12 months
|
For each hospitalization, the beginning and end dates will be recorded. |
12 months
|
|
Clinical improvement
기간: 12 months
|
Clinical improvement is scored via a point system from 0 to 3 at the end of the study. The points are added-up as follows:
|
12 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
기간: Baseline (day 0)
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
Baseline (day 0)
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
기간: 3 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
3 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
기간: 6 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
6 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
기간: 9 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
9 months
|
|
Medical outcomes study 36-Item Short Form Survey (SF-36)
기간: 12 months
|
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
12 months
|
|
EQ-5D-5L
기간: Baseline (day 0)
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
Baseline (day 0)
|
|
EQ-5D-5L
기간: 3 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
3 months
|
|
EQ-5D-5L
기간: 6 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
6 months
|
|
EQ-5D-5L
기간: 9 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
9 months
|
|
EQ-5D-5L
기간: 12 months
|
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension. |
12 months
|
|
St-George's Respiratory Questionnaire
기간: Baseline (day 0)
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
Baseline (day 0)
|
|
St-George's Respiratory Questionnaire
기간: 3 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
3 months
|
|
St-George's Respiratory Questionnaire
기간: 6 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
6 months
|
|
St-George's Respiratory Questionnaire
기간: 9 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
9 months
|
|
St-George's Respiratory Questionnaire
기간: 12 months
|
Scores range from 0 to 100, with higher scores indicating more limitations. |
12 months
|
|
Blood cell differential: neutrophil levels
기간: Baseline (day 0)
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
Baseline (day 0)
|
|
Blood cell differential: eosinophil levels
기간: Baseline (day 0)
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
Baseline (day 0)
|
|
Blood cell differential: neutrophil levels
기간: 12 months
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
12 months
|
|
Blood cell differential: eosinophil levels
기간: 12 months
|
A complete blood cell differential will be taken, including neutrophilia and eosinophilia. |
12 months
|
공동 작업자 및 조사자
협력자
수사관
- 연구 책임자: Jérémy Charriot, MD, University Hospital, Montpellier
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RECHMPL19_0074
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The general goal is to make the study data available to interested researchers as well as to provide proof of transparency for the study. Data (and an accompanying data dictionary) will be de-identified and potentially further cleaned or aggregated as the investigators deem necessary to protect participant anonymity.
Data will be made available to persons who address a reasonable request to the study director and fulfil the requirements stipulated by the French CNIL (Commission Nationale de l'Informatique et des Libertés : https://www.cnil.fr/professionnel).
IPD 공유 기간
As close to "real time" as possible, the following supporting information will be made public:
- Study Protocol (to be published in an appropriate journal).
- Statistical Analysis Plan
- Participant Information materials
- Analytic code
These will be posted and registered on osf.io and/or clinicaltrials.gov (if not published).
Datasets can be requested after the publication process has been completed.
IPD 공유 액세스 기준
The conditions under which members of the public will be granted access to datasets are:
- The data will be used/examined in a not-for-profit manner;
- The data will not be used in an attempt to identify a participant or group of participants;
- The user does not work for a private insurance company;
- The data will not be used in support of any kind of private insurance policy or health penalties;
- The data will be used/examined for the advancement of science/teaching while respecting participant/patient privacy and rights;
- The user will state why they wish to access the data.
- The appropriate CNIL approval has been obtained by the user.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .